Andrew Ho
Interventional Cardiology · Temecula, CANPI 1801919014
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $44,915 of the $72,026 with a category attached, or 62.4%. 52 manufacturers reported payments, led by AstraZeneca at 33.3% of the total. Reporting peaked in 2019 at $14,390 and has fallen 65.3% since, to $4,994 in 2025.
Across 908 payments — averaging $79.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$24K
- Johnson & Johnson$18K
- Abbott$10K
- Medtronic$6K
- Opsens Inc.$2K
- Philips North America LLC$1K
- plus $11K from 46 others
What the payments were for
- Consulting fees$8251%
- Speaking & faculty fees$44,91562%
- Travel & lodging$4,0826%
- Food & beverage$22,06731%
- Education$1370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$16,365
- BRILINTA$16,078
- ANDEXXA$6,620
- XIENCE V$3,000
- AVEIR$2,928
- OptoWire$2,000
- OptoMonitor$2,000
- VenaSeal$988
- Confirm Rx$633
- SYMPLICITY G3$432
- Indigo System$385
- JOT DX$353
- PRESSUREWIRE$266
- UPTRAVI$224
- OPSUMIT$224
- Micra$172
- AURORA EV-ICD MRI SURESCAN$165
- Edwards SAPIEN 3 Transcatheter Heart Valve$150
- CARDIOMEMS$132
- Sotalol Hydrochloride$131
How this compares
$72,026 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 228 | $299,418 |
| XareltoRivaroxaban | 130 | $150,351 |
| FarxigaDapagliflozin Propanediol | 56 | $72,871 |
| EntrestoSacubitril/Valsartan | 60 | $59,342 |
| MultaqDronedarone Hcl | 30 | $45,494 |
| Repatha SureclickEvolocumab | 39 | $32,659 |
| BrilintaTicagrelor | 31 | $31,204 |
| JardianceEmpagliflozin | 17 | $22,815 |
| Praluent PenAlirocumab | 23 | $11,243 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 88 | $10,721 |
| VascepaIcosapent Ethyl | 25 | $10,349 |
| Ranolazine ErRanolazine | 101 | $10,296 |
| Repatha SyringeEvolocumab | 13 | $6,930 |
| Metoprolol Succinate | 429 | $6,725 |
| Amiodarone Hcl | 82 | $5,808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $378 | $299,418228 claims |
| Johnson & JohnsonXarelto | $17,808 | $150,351130 claims |
| AstraZenecaFarxiga, Brilinta | $23,980 | $104,07587 claims |
| NovartisEntresto | $1,105 | $59,34260 claims |
| Sanofi-aventis U.S. LLCMultaq | $398 | $45,49430 claims |
| Boehringer IngelheimJardiance | $564 | $22,81517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Temecula
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.